GE HealthCare

GE HealthCare Technologies Inc. stands as a global leader in medical technology, pharmaceutical diagnostics, and digital healthcare solutions, serving healthcare providers in more than 160 countries with an installed base of over 4 million pieces of equipment. The company emerged as an independent public entity on January 4, 2023, when it spun off from General Electric following the conglomerate's strategic decision to separate into three focused companies. Trading on NASDAQ under the ticker GEHC, the company launched with approximately 51,000 employees worldwide and a bold vision for precision care that leverages advanced imaging, AI-powered diagnostics, and patient monitoring solutions.

With roots tracing back to 1893 and the founding of Victor Electric Company, GE HealthCare's legacy encompasses over a century of medical innovation. The company became a pioneer in X-ray equipment production in 1896, established leadership in CT scanners during the 1970s, and drove breakthroughs in MRI technology throughout the 1980s. Under the leadership of President and CEO Peter Arduini, who joined in December 2022, GE HealthCare has evolved into a $20 billion enterprise organized around four core divisions: Medical Imaging (including CT, MRI, molecular imaging, and X-ray systems), Ultrasound, Patient Care Solutions (monitoring, anesthesia, respiratory care, diagnostic cardiology, and infant care), and Pharmaceutical Diagnostics (contrast agents and radiopharmaceuticals).

In 2024, GE HealthCare delivered $19.7 billion in revenue with strong profitability improvements, achieving a 16.3% adjusted EBIT margin and investing over $1.3 billion in R&D. The company leads the medical device industry in FDA-authorized AI innovations, having secured more AI-enabled device authorizations than any other medical technology company. Recent breakthroughs include Photonova Spectra photon counting CT with Deep Silicon detector technology, Pristina Recon DL deep-learning mammography reconstruction, Flyrcado PET imaging agent for coronary artery disease detection, and the revolutionary Freelium MRI platform that uses less than 1% of the helium required by traditional systems. The company's CareIntellect for Oncology platform demonstrates its leadership in generative AI, bringing together multi-modal patient data with AI-powered clinical note summarization.

Looking ahead to 2025, GE HealthCare projects 2-3% organic revenue growth with adjusted EBIT margins of 16.7-16.8% and adjusted EPS growth of 3-6%. The company's strategy centers on enabling an early health model of care focused on earlier diagnosis, pre-symptomatic disease detection, and disease prevention. With approximately 53,000 employees and a market capitalization exceeding $36 billion, GE HealthCare continues to advance its mission of making life better for everyone across the world through precision healthcare innovation.